Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Molecure's Phase II KITE trial for OATD-01 in pulmonary sarcoidosis will continue without protocol changes following a positive IDMC review.
-
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
JACKSONVILLE, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients...
-
60 Degrees Pharma reached minimum enrollment for interim analysis of its hospitalized babesiosis trial, with data expected by October 6, 2026.
-
Tensive reports pivotal 12-month clinical trial data confirming REGENERA™ delivers natural breast reconstruction after lumpectomy
-
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today announced the launch of Medidata Plus. This clinical...
-
R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
-
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with iNHL in the watch-and-wait setting
-
OMEICOS has successfully completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA enabling a pivotal study in Primary Mitochondrial Disease (PMD).
-
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to invobenitug (procizumab) for the treatment of cardiogenic shock.